UNCY net incomeQ2 2026-$1.72M
UNCY net income was -$1.72M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.45M a year earlier. For the full fiscal 2025 it was -$26.55M, compared with -$36.73M in fiscal 2024.
Unicycive Therapeutics Inc. (UNCY) financials
For the twelve months ended Jun 30, 2026, Unicycive Therapeutics Inc. reported -$35.22M of net income.
- Net income, TTM
- -$35.22M
- Free cash flow, TTM
- -$27.85M
- Cash
- $44.19M
- Market cap
- $102.0M
FY2022FY2023
FY2020FY2025
FY2021FY2025
UNCY revenue and earnings growth
UNCY EPSQ2 2026-$0.06
UNCY diluted EPS was -$0.06 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.67.
UNCY free cash flowQ2 2026-$7.61M
UNCY free cash flow was -$7.61M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$8.43M a year earlier. For the full fiscal 2025 it was -$31.34M, compared with -$28.65M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $675.0K | $951.0K | - | - |
| Research and development | $9.12M | $20.01M | $12.90M | $12.44M | $6.08M | $1.01M |
| Selling, general and admin | $20.40M | $12.10M | $8.55M | $6.57M | $245.0K | $58.0K |
| Operating income | -$29.52M | -$32.12M | -$20.77M | -$18.05M | -$8.98M | -$2.02M |
| Interest expense | $71.0K | $71.0K | $82.0K | $6.0K | $628.0K | $244.0K |
| Net income | -$26.55M | -$36.73M | -$30.54M | -$18.06M | -$10.02M | -$2.26M |
| EPS, basic | -$1.67 | -$5.65 | -$12.80 | -$12.00 | -$8.60 | -$2.70 |
| EPS, diluted | -$1.67 | -$5.65 | -$12.80 | -$12.00 | -$8.60 | - |
| Diluted shares | 15.9M | 6.7M | 2.5M | 1.5M | 1.2M | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $29.20M | $26.14M | $9.70M | $455.0K | $16.58M | - |
| Short-term investments | $12.07M | - | - | - | - | - |
| Inventory | - | - | - | $2.19M | $1.83M | - |
| Current assets | $48.96M | $30.95M | $13.40M | $2.64M | $18.41M | $204.0K |
| Total assets | $49.13M | $31.67M | $14.19M | $2.82M | $18.74M | $204.0K |
| Current liabilities | $18.94M | $24.12M | $17.53M | $3.28M | $2.10M | $2.88M |
| Total liabilities | $18.94M | $24.24M | $18.00M | $3.28M | $2.26M | $2.88M |
| Shareholders' equity | $30.20M | $7.43M | -$3.81M | -$466.0K | $16.48M | -$2.67M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$31.32M | -$28.57M | -$18.28M | -$15.65M | -$5.77M | -$1.46M |
| Capital expenditures | $24.0K | $72.0K | $12.0K | $2.0K | $29.0K | - |
| Free cash flow | -$31.34M | -$28.65M | -$18.30M | -$15.65M | -$5.80M | - |
| Investing cash flow | -$12.10M | -$72.0K | -$12.0K | -$2.0K | -$29.0K | - |
| Financing cash flow | $46.47M | $45.09M | $27.54M | -$471.0K | $22.38M | $1.44M |
| Dividends paid | - | $1.09M | $900.0K | - | - | - |
| Stock-based compensation | $2.64M | $2.35M | $1.77M | $1.05M | $966.0K | - |
| Depreciation and amortization | - | - | - | $428.0K | $468.0K | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | -29.0% | - | - | - |
| Operating margin | - | - | -3077.6% | -1898.2% | - | - |
| Net margin | - | - | -4525.0% | -1898.8% | - | - |
| Free cash flow margin | - | - | -2710.4% | -1646.0% | - | - |
| Return on equity | -87.9% | -494.3% | - | - | -60.8% | - |
| Return on assets | -54.0% | -116.0% | -215.2% | -640.8% | -53.4% | -1109.8% |
| Current ratio | 2.59 | 1.28 | 0.76 | 0.81 | 8.75 | 0.07 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Research and development | $2.79M | $1.61M | $2.25M | $2.96M | $1.75M | $2.17M | $5.29M | $3.04M | $4.87M | $6.81M | $4.23M | $3.37M |
| Selling, general and admin | $7.35M | $6.83M | $4.97M | $4.38M | $5.21M | $5.82M | $3.97M | $3.21M | $2.53M | $2.39M | $2.08M | $2.57M |
| Operating income | -$10.14M | -$8.44M | -$7.22M | -$7.34M | -$6.96M | -$7.99M | -$9.26M | -$6.25M | -$7.40M | -$9.20M | -$6.31M | -$5.94M |
| Interest expense | - | - | $27.0K | $15.0K | $13.0K | $15.0K | $20.0K | $15.0K | $16.0K | $20.0K | $19.0K | $18.0K |
| Net income | -$1.72M | -$12.82M | -$14.67M | -$6.01M | -$6.45M | $570.0K | -$21.52M | -$4.10M | $9.86M | -$20.96M | -$7.80M | -$4.33M |
| EPS, basic | -$0.06 | -$0.54 | - | -$0.33 | -$0.52 | $0.04 | - | -$0.46 | $0.80 | -$6.10 | - | -$1.30 |
| EPS, diluted | -$0.06 | -$0.54 | - | -$0.33 | -$0.52 | -$0.50 | - | -$0.46 | -$1.50 | -$6.10 | - | -$1.30 |
| Diluted shares | 26.9M | 23.9M | - | 18.1M | 12.3M | 12.4M | - | 8.9M | 9.4M | 3.5M | - | 3.3M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $44.19M | $37.37M | $29.20M | $42.70M | $22.33M | $19.77M | $26.14M | $32.35M | $41.78M | $48.93M | $9.70M | $14.35M |
| Short-term investments | $17.24M | $17.21M | $12.07M | - | - | - | - | - | - | - | - | - |
| Current assets | $71.32M | $63.55M | $48.96M | $50.29M | $29.53M | $27.35M | $30.95M | $37.74M | $44.05M | $51.68M | $13.40M | $18.57M |
| Total assets | $72.03M | $64.41M | $49.13M | $50.61M | $30.00M | $27.95M | $31.67M | $38.57M | $44.70M | $52.38M | $14.19M | $19.44M |
| Current liabilities | $18.70M | $26.48M | $18.94M | $13.13M | $13.57M | $16.68M | $24.12M | $10.46M | $13.09M | $30.28M | $17.53M | $15.46M |
| Total liabilities | $18.76M | $26.70M | $18.94M | $13.13M | $13.57M | $16.68M | $24.24M | $10.72M | $13.36M | $30.65M | $18.00M | $16.01M |
| Shareholders' equity | $53.27M | $37.70M | $30.20M | $37.48M | $16.43M | $11.27M | $7.43M | -$27.85M | -$14.85M | -$24.46M | -$3.81M | $3.43M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.60M | -$6.24M | -$8.03M | -$5.96M | -$8.42M | -$8.90M | -$6.55M | -$9.25M | -$6.32M | -$6.46M | -$4.44M | -$4.42M |
| Capital expenditures | -$1.0K | $8.0K | $0 | $2.0K | $6.0K | $16.0K | $22.0K | $24.0K | $20.0K | $6.0K | $0 | $0 |
| Free cash flow | -$7.61M | -$6.25M | -$8.03M | -$5.96M | -$8.43M | -$8.92M | -$6.57M | -$9.28M | -$6.34M | -$6.46M | -$4.44M | -$4.42M |
| Investing cash flow | -$23.0K | -$5.16M | -$12.07M | -$2.0K | -$6.0K | -$16.0K | -$22.0K | -$24.0K | -$20.0K | -$6.0K | $0 | $0 |
| Financing cash flow | $14.44M | $19.57M | $6.61M | $26.33M | $10.98M | $2.55M | $365.0K | -$157.0K | -$811.0K | $45.69M | -$205.0K | -$51.0K |
| Dividends paid | - | - | - | - | - | - | $0 | $0 | - | - | $0 | $100.0K |
| Stock-based compensation | $2.88M | $754.0K | $777.0K | $730.0K | $571.0K | $563.0K | $582.0K | $605.0K | $641.0K | $522.0K | $550.0K | $929.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | - | - | - | -100.0% |
| Current ratio | 3.81 | 2.40 | 2.59 | 3.83 | 2.18 | 1.64 | 1.28 | 3.61 | 3.37 | 1.71 | 0.76 | 1.20 |
Source: XBRL data Unicycive Therapeutics Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Aug 14, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
UNCY peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| UNCY | - | - | -$35.22M | - | $102.0M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
UNCY FAQ
5 questionsIs UNCY profitable?
No. Unicycive Therapeutics Inc. reported a net loss of $35.22M for the twelve months ended Jun 30, 2026.How much cash and debt does UNCY have?
Unicycive Therapeutics Inc. reported $44.19M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is UNCY free cash flow?
Unicycive Therapeutics Inc. generated -$27.85M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$27.84M less capital expenditures.When did UNCY last report financial results?
The latest statements here come from Unicycive Therapeutics Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this UNCY financial data come from?
Quantisnow builds these statements from the structured XBRL data Unicycive Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.